Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Crossref DOI link: https://doi.org/10.1007/s40744-020-00201-y
Published Online: 2020-03-29
Published Print: 2020-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Best, Jennie H.
Vlad, Steven C.
Tominna, Lenore
Abbass, Ibrahim
Funding for this research was provided by:
Genentech
Text and Data Mining valid from 2020-03-29
Version of Record valid from 2020-03-29
Article History
Received: 7 February 2020
First Online: 29 March 2020